Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer

Enrica Martinelli, Andrea Fattorossi, Alessandra Battaglia, Marco Petrillo, Giuseppina Raspaglio, Gian Franco Zannoni, Mara Fanelli, Daniela Gallo, Giovanni Scambia

Research output: Contribution to journalArticle

Abstract

Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUBB3 antibodies was investigated in 49 untreated OC patients and 44 healthy individuals by an in-house developed ELISA that used recombinant TUBB3 as the antigen. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of the assay. Anti-TUBB3 antibodies discriminated OC patients and healthy individuals with excellent sensitivity and specificity (91.8% and 90.9%, respectively). In multivariate analysis, anti-TUBB3 antibody level emerged as an independent prognostic factor for progression free and overall survival. The ELISA was then optimized using a biotin-labeled TUBB3 C-terminal peptide424-450 instead of recombinant TUBB3 as the antigen and streptavidin-coated plates. The diagnostic role of the anti-TUBB3 antibodies was studied in an independent series of 99 OC patients and 80 gynecological benign disease patients. ROC-curve analysis showed a valuable diagnostic potential for serum anti-TUBB3 antibodies to identify OC patients with higher sensitivity and specificity (95.3% and 97.6%, respectively). Overall, our results provide evidence that preoperative anti-TUBB3 antibody level is a promising diagnostic and prognostic biomarker for the management of OC patients.

Original languageEnglish
Pages (from-to)358-365
Number of pages8
JournalTranslational Oncology
Volume11
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Tubulin
Ovarian Neoplasms
Anti-Idiotypic Antibodies
Biomarkers
Antibodies
ROC Curve
Enzyme-Linked Immunosorbent Assay
Antigens
Sensitivity and Specificity
Streptavidin
Biotin
Serum
Disease-Free Survival
Antibody Formation
Multivariate Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. / Martinelli, Enrica; Fattorossi, Andrea; Battaglia, Alessandra; Petrillo, Marco; Raspaglio, Giuseppina; Zannoni, Gian Franco; Fanelli, Mara; Gallo, Daniela; Scambia, Giovanni.

In: Translational Oncology, Vol. 11, No. 2, 01.04.2018, p. 358-365.

Research output: Contribution to journalArticle

Martinelli, E, Fattorossi, A, Battaglia, A, Petrillo, M, Raspaglio, G, Zannoni, GF, Fanelli, M, Gallo, D & Scambia, G 2018, 'Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer', Translational Oncology, vol. 11, no. 2, pp. 358-365. https://doi.org/10.1016/j.tranon.2018.01.016
Martinelli, Enrica ; Fattorossi, Andrea ; Battaglia, Alessandra ; Petrillo, Marco ; Raspaglio, Giuseppina ; Zannoni, Gian Franco ; Fanelli, Mara ; Gallo, Daniela ; Scambia, Giovanni. / Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. In: Translational Oncology. 2018 ; Vol. 11, No. 2. pp. 358-365.
@article{0e9d2bc9621f487b9cd12923d12b0663,
title = "Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer",
abstract = "Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUBB3 antibodies was investigated in 49 untreated OC patients and 44 healthy individuals by an in-house developed ELISA that used recombinant TUBB3 as the antigen. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of the assay. Anti-TUBB3 antibodies discriminated OC patients and healthy individuals with excellent sensitivity and specificity (91.8{\%} and 90.9{\%}, respectively). In multivariate analysis, anti-TUBB3 antibody level emerged as an independent prognostic factor for progression free and overall survival. The ELISA was then optimized using a biotin-labeled TUBB3 C-terminal peptide424-450 instead of recombinant TUBB3 as the antigen and streptavidin-coated plates. The diagnostic role of the anti-TUBB3 antibodies was studied in an independent series of 99 OC patients and 80 gynecological benign disease patients. ROC-curve analysis showed a valuable diagnostic potential for serum anti-TUBB3 antibodies to identify OC patients with higher sensitivity and specificity (95.3{\%} and 97.6{\%}, respectively). Overall, our results provide evidence that preoperative anti-TUBB3 antibody level is a promising diagnostic and prognostic biomarker for the management of OC patients.",
author = "Enrica Martinelli and Andrea Fattorossi and Alessandra Battaglia and Marco Petrillo and Giuseppina Raspaglio and Zannoni, {Gian Franco} and Mara Fanelli and Daniela Gallo and Giovanni Scambia",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2018.01.016",
language = "English",
volume = "11",
pages = "358--365",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer

AU - Martinelli, Enrica

AU - Fattorossi, Andrea

AU - Battaglia, Alessandra

AU - Petrillo, Marco

AU - Raspaglio, Giuseppina

AU - Zannoni, Gian Franco

AU - Fanelli, Mara

AU - Gallo, Daniela

AU - Scambia, Giovanni

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUBB3 antibodies was investigated in 49 untreated OC patients and 44 healthy individuals by an in-house developed ELISA that used recombinant TUBB3 as the antigen. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of the assay. Anti-TUBB3 antibodies discriminated OC patients and healthy individuals with excellent sensitivity and specificity (91.8% and 90.9%, respectively). In multivariate analysis, anti-TUBB3 antibody level emerged as an independent prognostic factor for progression free and overall survival. The ELISA was then optimized using a biotin-labeled TUBB3 C-terminal peptide424-450 instead of recombinant TUBB3 as the antigen and streptavidin-coated plates. The diagnostic role of the anti-TUBB3 antibodies was studied in an independent series of 99 OC patients and 80 gynecological benign disease patients. ROC-curve analysis showed a valuable diagnostic potential for serum anti-TUBB3 antibodies to identify OC patients with higher sensitivity and specificity (95.3% and 97.6%, respectively). Overall, our results provide evidence that preoperative anti-TUBB3 antibody level is a promising diagnostic and prognostic biomarker for the management of OC patients.

AB - Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum anti-TUBB3 antibodies was investigated in 49 untreated OC patients and 44 healthy individuals by an in-house developed ELISA that used recombinant TUBB3 as the antigen. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of the assay. Anti-TUBB3 antibodies discriminated OC patients and healthy individuals with excellent sensitivity and specificity (91.8% and 90.9%, respectively). In multivariate analysis, anti-TUBB3 antibody level emerged as an independent prognostic factor for progression free and overall survival. The ELISA was then optimized using a biotin-labeled TUBB3 C-terminal peptide424-450 instead of recombinant TUBB3 as the antigen and streptavidin-coated plates. The diagnostic role of the anti-TUBB3 antibodies was studied in an independent series of 99 OC patients and 80 gynecological benign disease patients. ROC-curve analysis showed a valuable diagnostic potential for serum anti-TUBB3 antibodies to identify OC patients with higher sensitivity and specificity (95.3% and 97.6%, respectively). Overall, our results provide evidence that preoperative anti-TUBB3 antibody level is a promising diagnostic and prognostic biomarker for the management of OC patients.

UR - http://www.scopus.com/inward/record.url?scp=85044727338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044727338&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2018.01.016

DO - 10.1016/j.tranon.2018.01.016

M3 - Article

AN - SCOPUS:85044727338

VL - 11

SP - 358

EP - 365

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -